Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma

NCT00017069 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00017069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2001
Completion date
January 31, 2005
Enrollment
Not reported
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm